Systematic thyroid screening in myotonic dystrophy: link between thyroid volume and insulin resistance.


Journal

Orphanet journal of rare diseases
ISSN: 1750-1172
Titre abrégé: Orphanet J Rare Dis
Pays: England
ID NLM: 101266602

Informations de publication

Date de publication:
13 02 2019
Historique:
received: 12 07 2018
accepted: 03 02 2019
entrez: 15 2 2019
pubmed: 15 2 2019
medline: 20 4 2019
Statut: epublish

Résumé

Myotonic dystrophy (DM1), a neuromuscular disease related to DMPK gene mutations, is associated to endocrine disorders and cancer. A routine endocrine work-up, including thyroid ultrasound (US), was conducted in 115 genetically-proven DM1 patients in a neuromuscular reference center. The aim of this study was to determine the prevalence and the causes of US thyroid abnormalities in DM1. In the whole population (age 45.1 ± 12.2 years, 61.7% female), palpable nodules or goiters were present in 29.2%. The percentage of US goiter (thyroid volume > 18 mL) and US nodules were, respectively, 38.3 and 60.9%. Sixteen of the 115 patients had a thyroidectomy, after 22 fine-needle aspiration cytology guided by thyroid imaging reporting and data system (TIRADS) classification. Six micro- (1/6 pT3) and 3 macro-papillary thyroid carcinoma (PTCs) (2/3 intermediate risk) were diagnosed (7.9% of 115). Thyroid US led to the diagnosis of 4 multifocal and 2 unifocal (including 1 macro-PTC) non-palpable PTCs. Ultrasound thyroid volume was positively correlated to body mass index (BMI) (p = 0.015) and parity (p = 0.036), and was inversely correlated to TSH (p < 0.001) and vitamin D levels (p = 0.023). The BMI, the frequencies of glucose intolerance and PTC were significantly higher in UsGoiter versus non-UsGoiter groups. In this systematically screened DM1 cohort, the frequency of UsGoiter, mainly associated to BMI, was about 40%, US nodules 60%, thyroidectomies 13-14%, and PTCs 8%, two-thirds of them being micro-PTCs with good prognosis. Therefore, a systematic screening remains debatable. A targeted US screening in case of clinical abnormality or high BMI seems more appropriate.

Sections du résumé

BACKGROUND
Myotonic dystrophy (DM1), a neuromuscular disease related to DMPK gene mutations, is associated to endocrine disorders and cancer. A routine endocrine work-up, including thyroid ultrasound (US), was conducted in 115 genetically-proven DM1 patients in a neuromuscular reference center. The aim of this study was to determine the prevalence and the causes of US thyroid abnormalities in DM1.
RESULTS
In the whole population (age 45.1 ± 12.2 years, 61.7% female), palpable nodules or goiters were present in 29.2%. The percentage of US goiter (thyroid volume > 18 mL) and US nodules were, respectively, 38.3 and 60.9%. Sixteen of the 115 patients had a thyroidectomy, after 22 fine-needle aspiration cytology guided by thyroid imaging reporting and data system (TIRADS) classification. Six micro- (1/6 pT3) and 3 macro-papillary thyroid carcinoma (PTCs) (2/3 intermediate risk) were diagnosed (7.9% of 115). Thyroid US led to the diagnosis of 4 multifocal and 2 unifocal (including 1 macro-PTC) non-palpable PTCs. Ultrasound thyroid volume was positively correlated to body mass index (BMI) (p = 0.015) and parity (p = 0.036), and was inversely correlated to TSH (p < 0.001) and vitamin D levels (p = 0.023). The BMI, the frequencies of glucose intolerance and PTC were significantly higher in UsGoiter versus non-UsGoiter groups.
CONCLUSION
In this systematically screened DM1 cohort, the frequency of UsGoiter, mainly associated to BMI, was about 40%, US nodules 60%, thyroidectomies 13-14%, and PTCs 8%, two-thirds of them being micro-PTCs with good prognosis. Therefore, a systematic screening remains debatable. A targeted US screening in case of clinical abnormality or high BMI seems more appropriate.

Identifiants

pubmed: 30760283
doi: 10.1186/s13023-019-1019-3
pii: 10.1186/s13023-019-1019-3
pmc: PMC6375124
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

42

Références

Arch Intern Med. 2000 Mar 13;160(5):661-6
pubmed: 10724051
Eur J Endocrinol. 2002 Mar;146(3):397-405
pubmed: 11888847
Clin Endocrinol (Oxf). 2007 Aug;67(2):247-9
pubmed: 17524034
J Radiol. 2011 Jul-Aug;92(7-8):701-13
pubmed: 21819912
JAMA. 2011 Dec 14;306(22):2480-6
pubmed: 22166607
Mayo Clin Proc. 2012 Feb;87(2):130-5
pubmed: 22237010
J Neurol. 2012 May;259(5):912-20
pubmed: 22349862
J Neurol. 2012 Oct;259(10):2161-6
pubmed: 22619053
Arq Bras Endocrinol Metabol. 2013 Mar;57(2):120-5
pubmed: 23525289
J Neurol. 2013 Sep;260(9):2330-4
pubmed: 23754696
J Neurol Sci. 2013 Aug 15;331(1-2):132-5
pubmed: 23809192
J Korean Med Sci. 2014 May;29(5):676-9
pubmed: 24851024
Muscle Nerve. 2015 Aug;52(2):273-7
pubmed: 25487787
Lancet Diabetes Endocrinol. 2015 Apr;3(4):286-95
pubmed: 25591468
Int J Clin Exp Med. 2015 Jul 15;8(7):11379-87
pubmed: 26379953
Medicine (Baltimore). 2015 Sep;94(39):e1639
pubmed: 26426654
Eur J Neurol. 2016 Mar;23(3):542-7
pubmed: 26508558
Ann Endocrinol (Paris). 2015 Dec;76(6):684-9
pubmed: 26593863
Physiol Rev. 2016 Jan;96(1):365-408
pubmed: 26681795
J Neurol. 2016 Mar;263(3):492-8
pubmed: 26739382
World J Surg. 2016 Mar;40(3):516-22
pubmed: 26744340
PLoS One. 2016 Feb 05;11(2):e0148264
pubmed: 26849574
Muscle Nerve. 2016 Oct;54(4):783-5
pubmed: 27064430
Neurology. 2016 Sep 20;87(12):1250-7
pubmed: 27558368
J Clin Oncol. 2016 Oct 20;34(30):3672-3679
pubmed: 27601555
Rev Neurol (Paris). 2016 Oct;172(10):572-580
pubmed: 27665240
J Steroid Biochem Mol Biol. 2017 Oct;173:258-264
pubmed: 28007531
Thyroid. 2017 Apr;27(4):481-483
pubmed: 28114862
Int J Endocrinol. 2017;2017:8401518
pubmed: 28356911
JAMA. 2017 Apr 4;317(13):1338-1348
pubmed: 28362912
Front Cell Neurosci. 2017 Apr 20;11:101
pubmed: 28473756
Muscle Nerve. 2018 Feb;57(2):316-320
pubmed: 28662292
J Pathol Transl Med. 2017 Nov;51(6):521-527
pubmed: 29017314
Int J Cancer. 2018 Mar 15;142(6):1174-1181
pubmed: 29114849
Muscle Nerve. 2018 Oct;58(4):517-522
pubmed: 30028904
J Med Genet. 1994 Nov;31(11):891-2
pubmed: 7853378

Auteurs

Adrien Ben Hamou (A)

CHU Lille, Endocrinology, Diabetology and Metabolism, F-59000, Lille, France. adrien.benhamou@hotmail.fr.
Department of Endocrinology, Diabetology and Metabolism, CHR-U Lille, 1, Rue Polonovski, 59037, Lille, France. adrien.benhamou@hotmail.fr.

Stéphanie Espiard (S)

CHU Lille, Endocrinology, Diabetology and Metabolism, F-59000, Lille, France.

Christine Do Cao (C)

CHU Lille, Endocrinology, Diabetology and Metabolism, F-59000, Lille, France.

Miriam Ladsous (M)

CHU Lille, Endocrinology, Diabetology and Metabolism, F-59000, Lille, France.

Camille Loyer (C)

CHU Lille, Endocrinology, Diabetology and Metabolism, F-59000, Lille, France.

Alexandre Moerman (A)

CHU Lille, Clinical Genetics, F-59000, Lille, France.

Samuel Boury (S)

CHU Lille, Radiology, F-59000, Lille, France.

Maéva Kyheng (M)

CHU Lille, EA 2694 - Public Health, Epidemiology and Quality of Care, F-59000, Lille, France.

Claire-Marie Dhaenens (CM)

Univ Lille, Inserm, CHU Lille, UMR 837-1, Alzheimer & Tauopathies, F-59000, Lille, France.

Vincent Tiffreau (V)

CHU Lille Neuromuscular Reference Center, F-59000, Lille, France.

Pascal Pigny (P)

CHU Lille, Institute of Biochemistry and Molecular Biology - Biology Center, F-59000, Lille, France.

Gilles Lebuffe (G)

CHU Lille, Anesthesiology, F-59000, Lille, France.

Robert Caiazzo (R)

CHU Lille, General and Endocrine Surgery, F-59000, Lille, France.
Univ Lille, Inserm, CHU Lille, UMR 1190 Translational Research in Diabetes, F-59000, Lille, France.
EGID European Genomics Institute for Diabetes, CHU Lille, F-59000, Lille, France.

Sébastien Aubert (S)

CHU Lille, Institute of Biochemistry and Molecular Biology - Pathology Center, F-59000, Lille, France.

Marie Christine Vantyghem (MC)

CHU Lille, Endocrinology, Diabetology and Metabolism, F-59000, Lille, France. mc-vantyghem@chru-lille.fr.
CHU Lille Neuromuscular Reference Center, F-59000, Lille, France. mc-vantyghem@chru-lille.fr.
Univ Lille, Inserm, CHU Lille, UMR 1190 Translational Research in Diabetes, F-59000, Lille, France. mc-vantyghem@chru-lille.fr.
EGID European Genomics Institute for Diabetes, CHU Lille, F-59000, Lille, France. mc-vantyghem@chru-lille.fr.
Department of Endocrinology, Diabetology and Metabolism, CHR-U Lille, 1, Rue Polonovski, 59037, Lille, France. mc-vantyghem@chru-lille.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH